Toepfer Stephanie, Keniya Mikhail V, Lackner Michaela, Monk Brian C
Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand.
Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria.
J Fungi (Basel). 2024 Oct 7;10(10):698. doi: 10.3390/jof10100698.
Limited antifungal treatment options and drug resistance require innovative approaches to effectively combat fungal infections. Combination therapy is a promising strategy that addresses these pressing issues by concurrently targeting multiple cellular sites. The drug targets usually selected for combination therapy are from different cellular pathways with the goals of increasing treatment options and reducing development of resistance. However, some circumstances can prevent the implementation of combination therapy in clinical practice. These could include the increased risk of adverse effects, drug interactions, and even the promotion of drug resistance. Furthermore, robust clinical evidence supporting the superiority of combination therapy over monotherapy is limited and underscores the need for further research. Despite these challenges, synergies detected with different antifungal classes, such as the azoles and echinocandins, suggest that treatment strategies can be optimized by better understanding the underlying mechanisms. This review provides an overview of multi-targeting combination strategies with a primary focus on infections.
有限的抗真菌治疗选择和耐药性需要创新方法来有效对抗真菌感染。联合治疗是一种很有前景的策略,它通过同时针对多个细胞位点来解决这些紧迫问题。通常选择用于联合治疗的药物靶点来自不同的细胞途径,目的是增加治疗选择并减少耐药性的产生。然而,某些情况可能会阻碍联合治疗在临床实践中的实施。这些情况可能包括不良反应风险增加、药物相互作用,甚至促进耐药性。此外,支持联合治疗优于单一疗法的有力临床证据有限,这凸显了进一步研究的必要性。尽管存在这些挑战,但不同抗真菌类别(如唑类和棘白菌素类)之间检测到的协同作用表明,可以通过更好地理解潜在机制来优化治疗策略。本综述概述了多靶点联合策略,主要关注感染。